Drugs: Ultra-orphan Diseases

House of Lords written question – answered at on 26 October 2010.

Alert me about debates like this

Photo of Lord Walton of Detchant Lord Walton of Detchant Crossbench

To ask Her Majesty's Government what steps they will take to ensure that the National Institute for Health and Clinical Excellence considers the Citizens Council's recommendations Deviating from the threshold, relating to the assessment of the cost-effectiveness of new treatments for ultra-orphan diseases.

Photo of Earl Howe Earl Howe The Parliamentary Under-Secretary of State for Health

This is a matter for the National Institute for Health and Clinical Excellence (NICE) as an independent body.

In January 2009, NICE issued supplementary advice to its appraisal committees on the appraisal of life-extending end-of-life drugs. In developing the advice, NICE took account of the Citizens' Council's views on the circumstances in which it may be appropriate to recommend a treatment where the cost per quality adjusted life year is above the normal threshold range.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.